A Phase 1 Study of TAK-676, a Novel STING Agonist, Plus Pembrolizumab Following Radiation Therapy in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC), Triple-Negative Breast Cancer (TNBC), or Squamous-Cell Carcinoma of the Head and Neck (SCCHN)
| Autor: | Gerber, N.K., Chmura, S.J., Luke, J.J., Shiao, S.L., Basho, R., Iams, W.T., Page, D.B., Li, C., Gregory, R.C., Shaw, M.H., Horn, K.H., Gibbs, J., Appleman, V.A., Berger, A., Abu-Yousif, A.O., Lineberry, N.B., Stumpo, K.F., Elfiky, A., Cooper, B. |
|---|---|
| Zdroj: | In International Journal of Radiation Oncology, Biology, Physics 1 November 2022 114(3) Supplement:e40-e40 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|